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We previously showed that high expression levels of SOX9 correlate with hepatocellular carcinoma
(HCC) progression. However, the exact role that SOX9 plays in HCC remains unclear. In this study, we
ﬁrstly conﬁrmed that miRNA-101 directly targets SOX9 in HCC. Ectopic expression of miR-101
signiﬁcantly inhibited HCC cell proliferation and tumorigenicity by targeting SOX9. Moreover, the
down-regulation of miR-101 in clinical HCC tissues correlates with tumor aggressiveness and poor
prognosis. Therefore, miR-101 may suppress HCC tumor progression by down-regulating SOX9.
MiR-101 may be a potential prognostic marker and therapeutic target for HCC.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfthmost frequentmalig-
nancies and the third leading cause of cancer-related deaths world-
wide [1]. The distribution of HCC is unbalanced throughout the
world, with the highest incidence in Asia and Sub-Saharan Africa,
especially in China. As a notoriously aggressive solid tumor, HCC
is characterized by fast inﬁltrating growth, early metastasis, high-
grade malignancy, and poor prognosis. This cancer often develops
as a consequence of underlying liver diseases such as hepatitis B
virus (HBV) and hepatitis C virus (HCV) infections, and is almost
associated with cirrhosis [2]. At present, surgical hepatic resection
and liver transplantation are the only curative treatment modality
to confer survival beneﬁt in HCC patients. However, the overall 5-
year survival rate for HCC patients is still only 5% [3]. Therefore, it
is necessary to elucidate the molecular mechanisms underlying
HCC progression and identify novel therapeutic targets in order to
improve the clinical outcome of patients with this cancer.chemical Societies. Published by E
9.
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to this article.MicroRNAs (miRNAs), a class of genes encoding small RNA mol-
ecules (19–22 nucleotides), play important roles in regulating pro-
tein expression by inhibiting translation or inducing mRNA
degradation by binding to the 30-untranslational region (30-UTR)
of target mRNAs [4]. Beyond the involvement in diverse physiolog-
ical and pathological processes, the increasing evidences have well
demonstrated that deregulation or dysfunction of miRNAs can con-
tribute to carcinogenesis and cancer development [5]. The roles of
miRNAs in different cancers may be dependent on cancer type [6].
Some miRNAs may act as oncogenes overexpressing in cancers and
contributing to the transformed phenotypes. These oncogenic
miRNAs function by suppressing tumor suppressor genes. Other
miRNAs may act as tumor suppressors down-regulating in cancers
and allowing the expression of oncogenes. As far as HCC is
concerned, accumulating evidence indicates that deregulation of
miRNAs can contribute to HCC development by inﬂuencing cell
growth, apoptosis, migration, or invasion. Aberrant miRNA expres-
sion has also been demonstrated to associate with clinical features
of HCC, such as stage, differentiation, prognosis, and response to
adjuvant therapy [7,8]. Therefore, it is necessary to identify more
miRNAs as prognosis predictor or therapeutic target for this cancer.
The transcription factor SOX9 (sex determining region Y [SRY]
related high-mobility group box 9) is a member of the SRY (sexlsevier B.V. All rights reserved.
Table 1
Clinicopathological features and the expression of miRNA-101 in 130 hepatocellular
carcinoma patients.
Clinicopathological features Case MiRNA-101 expression
frequency (n, %)
P
High Low
Age (years)
650 72 33 (45.83) 39 (54.17) NS
>50 58 22 (37.93) 36 (62.07)
Gender
Male 96 40 (41.67) 56 (58.33) NS
Female 34 15 (44.12) 19 (55.88)
Tumor stage
T1 23 23 (100.00) 0 (0) 0.02
T2 40 20 (50.00) 20 (50.00)
T3 52 12 (23.08) 40 (76.92)
T4 15 0 (0) 15 (100.00)
Tumor grade
G1 31 31 (100.00) 0 (0) 0.008
G2 76 24 (31.58) 52 (68.42)
G3 23 0 (0) 23 (100.00)
Growth pattern
Trabecular 101 44 (43.56) 57 (56.44) NS
Non-trabecular 29 11 (37.93) 18 (62.07)
Cirrhosis
Yes 86 36 (41.87) 50 (58.13) NS
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determination, chondrogenesis, respiratory epithelium develop-
ment, melanocyte differentiation, and the differentiation of Paneth
cells in the gut [10]. Recent studies have detected the expression of
SOX9 inmultiple tissues during embryogenesis, including cartilage,
neural crest, notochord, kidney, pancreas, and endocardial cushions
of the heart [11]. Besides these ﬁndings, SOX9 has also been demon-
strated to play a role in a variety of malignancies. For example,
Wang et al. [12] detected the expression of SOX9 in prostate cancer
cells contributes to tumor growth and invasion; Aleman et al. [13]
found that SOX9 hypermethylation in primary bladder tumours
was present more than half of the cases and was signiﬁcantly
associated with tumour grade and overall survival; Malki et al.
[14] shown that the embryonic male prostaglandin D synthase/
SOX9 pathway was expressed at both the RNA and protein levels
in different types of human ovarian tumors, pointing to SOX9 as a
possible diagnostic marker for ovarian carcinomas. Especially, the
previous study of our group detected the up-regulation of SOX9
at mRNA and protein levels in clinical HCC tissues compared with
their adjacent non-neoplastic tissues [15]. Our data also indicated
that high SOX9 expression is associated with advanced tumor
progression and poor clinical outcome of HCC patients [15]. On
the basis of these ﬁndings, the aim of the present study was to
elucidate the mechanism of SOX9 plays in HCC.No 44 19 (43.18) 25 (56.82)
Underlying liver disease
Alcoholic 25 11 (44.00) 14 (56.00) NS
Hepatitis B 49 20 (40.82) 29 (59.18)
Hepatitis C 35 15 (42.86) 20 (57.14)
Unknown 21 9 (42.86) 12 (57.14)2. Materials and methods
2.1. Cell culture
Human HCC cell line HepG2 was obtained from the American
Type Culture Collection (Manassas, VA, USA) and was cultured in
DMEM (Invitrogen, USA) supplemented with 10% fetal bovine ser-
um (Gibico, USA), 2 mM L-glutamine and antibiotics. Normal hu-
man liver cell line HL-7702 was obtained from the American Type
Culture Collection (Manassas, VA, USA) and was maintained in
RPMI 1640 medium (Invitrogen, USA) supplemented with 10% fetal
bovine serum (Gibico, USA). Two cell lines were both maintained at
37 C in a humidiﬁed chamber supplemented with 5% CO2.
2.2. Patients and tissue samples
The study was approved by the Research Ethics Committee of
302nd Hospital of PLA, Beijing, China. Informed consent was ob-
tained from all of the patients. All specimens were handled and
made anonymous according to the ethical and legal standards.
A total of 130 self-pairs of HCC specimens and adjacent non-
neoplastic liver tissues were snap-frozen in liquid nitrogen and
stored at 80 C following surgery for qRT-PCR assay. All the tis-
sues were obtained from 130 patients with primary HCC who
underwent a curative liver resection at the 302nd Hospital of
PLA, Beijing, China. These patients were diagnosed as HCC between
2001 and 2006. None of the patients recruited in this study had
chemotherapy or radiotherapy before the surgery. HCC diagnosis
was based on World Health Organization (WHO) criteria. Tumor
differentiation was deﬁned according to the Edmondson grading
system. Liver function was assessed using the Child-Pugh scoring
system. Tumor staging was determined according to the sixth edi-
tion of the tumor-node-metastasis (TNM) classiﬁcation of the
International Union against Cancer. The clinicopathological fea-
tures of 130 patients are summarized in Table 1.
The median follow-up period was 8.6 years. Postoperative sur-
veillance included routine clinical and laboratory examinations
every third month, computed tomography scans of the abdomen,
and radiographs of the chest every third month. After 5 years, the
examination interval was extended to 12 months.2.3. Target prediction
An online program Target-Scan (release human 6.2) was used
for predicting miRNAs that might target SOX9.
2.4. EGFP-miR-101 expression vector and cellular transfection
We obtained the commercial Pre-miR-101 expression vector
(human pMIR101-1PA-1) with the following sequence: 50-TGC
CCT GGC TCA GTT ATC ACA GTG CTG ATG CTG TCT ATT CTA AAG
GTA CAG TAC TGT GAT AAC TGA AGG ATG GCA-30, Pre-miR-145
expression vector as a positive control with the following se-
quence: 50- CAC CUU GUC CUC ACG GUC CAG UUU UCC CAG GAA
UCC CUU AGA UGC UAA GAU GGG GAU UCC UGG AAA UAC UGU
UCU UGA GGU CAU GGU U-30, and the same negative-vector as a
negative control from System Bioscience (Mountain View, CA). A
ﬂuorescent marker (GFP) is also present to monitor cells that are
positive for transfection. HepG2 cells were transfected through
Fugene transfecting agents (Roche) with hsa-miR-101 vector,
hsa-miR-145 vector (positive control), and negative control (NC)
following the manufacturer’s instructions, respectively.
2.5. qRT-PCR
The qRT-PCR analysis formiRNAwas performed according to the
similar protocol of the previous studies. Brieﬂy, total RNA, including
miRNA, was extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. After that,
the total RNA was reversely transcribed using the corresponding
RT Primer and the TaqMan MicroRNA Reverse Transcription Kit
(Applied Biosystems). U6 small RNAwas used as an internal control
for normalization and quantiﬁcation of the target miRNA expres-
sion. The speciﬁcity of ampliﬁcation was conﬁrmed by melting
curve analysis and also by running PCR products on agarose gels
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evaluated using the comparative cycle threshold (CT) method. All
experimentswere done in triplicate. Mean normalized gene expres-
sion ± S.E. was calculated from independent experiments.
2.6. RNA interference and cellular transfection
HepG2 cells were seeded into 6-well plates and incubated over-
night, and then transfected using Lipofectamine™ 2000 transfec-
tion reagent (Invitrogen) according to the manufacturer’s
instructions. The siRNAs against SOX9 (siSOX9_2) and the control
siRNA were synthesized by QIAGEN China Co., Shanghai, China.
For every 105 cells, 0.5 lg SOX9 siRNA or control siRNA was diluted
and mixed with 3 ll transfection reagent. After mixing and incuba-
tion for 30 min, the transfection mixture was added to the cells.
After 6 h, medium was changed to growth medium. HepG2 cells
were used for functional assay 24 h after transfection.
2.7. Western blot
The Western blot protocol and semiquantitative analysis were
carried out following the protocol of our previous study. SOX9 anti-
body (rabbit polyclonal antibody, dilution 1:50, Santa Cruz Bio-
technology Inc., USA) was used, and GAPDH antibody (CW0266,
dilution 1:1,000, CoWin Biotech) was used as internal control. All
experiments were done in triplicate. Mean normalized gene
expression ± S.E. was calculated from independent experiments.
2.8. Luciferase reporter assay
The miR-101-targeted gene was evaluated by using a luciferase
reporter assay in HepG2 cells following the protocol of the previ-
ous studies. Brieﬂy, the human SOX9 30-UTR luciferase reporter
construct was generated by cloning SOX9 mRNA 30-UTR sequence
into the 30-UTR region of the pGL3 luciferase reporter vector (Pro-
mega Corporation, Madison WI, USA). The miR-101 target site-
deleted SOX9 30-UTR luciferase reporter construct was generated
by PCR fragments of SOX9 30-UTR luciferase reporter construct
lacking the target site and ligated. HepG2 cells were cultivated in
24-well plates and co-transfected using Fugene (Roche) with
100 ng of pGL3-SOX9-miR-101 constructs, 10 ng miR-101 mimic
or NC mimic, and 2 ng pRL-SV40 RLuci vector (Promega). The lucif-
erase activity assay was performed 24 h after transfection using
the dual-luciferase reporter assay system (Promega Corporation,
Madison WI) according to the manufacturer’s instructions.
2.9. In vitro cell proliferation assay
The in vitro cell proliferation of HepG2 cells was measured
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) method following the protocol of the previous
studies. Brieﬂy, cells were seeded into 96-well plates and transfec-
ted. At 48 h after transfection, 20 ll MTT solution (Sigma, USA) was
added into the culture medium for 4 h incubation. Then, the med-
ium was replaced by 0.1 ml of DMSO (Sigma, St. Louis, MO, USA)
and plates were shaken at room temperature for 10 min. The
absorbance of each sample was recorded at 490 nm. All experi-
ments were done in triplicate. Mean normalized gene expres-
sion ± S.E. was calculated from independent experiments.
2.10. In vitro invasion and migration assay
Cell invasion and migration were respectively analyzed by
Matrigel coated and uncoated transwell cell culture chambers
(8 lm pore size, Millipore, Billerica, MA, USA). Brieﬂy, 48 h after
transfection, cells were resuspended in serum-free medium, and200 ll of the cell suspension (4  104 cells) was seeded into the
upper chambers. Medium with 5% FBS was added into the lower
chambers as a chemoattractant. After 40 h of incubation, the cells
that did not migrate or invade after 24 h were removed from the
upper face of the ﬁlters by scrubbing with a cotton swab, after
which the membrane was ﬁxed with 4% formaldehyde for 10 min
at room temperature and stained with 0.5% crystal violet for
10 min. Finally, the migratory and invasive cells were manually
counted at 200magniﬁcation from ten different ﬁelds of each ﬁl-
ter. All experiments were done in triplicate. Mean normalized gene
expression ± S.E. was calculated from independent experiments.
2.11. Statistical analysis
The software of SPSS version13.0 for Windows (SPSS Inc, IL,
USA) and SAS 9.1 (SAS Institute, Cary, NC) was used for statistical
analysis. Continuous variables were expressed as X  s: Fisher’s ex-
act test and the v2 test were performed to assess associations be-
tween miR-101 expression and clinicopathological parameters.
The Kaplan–Meier method was used for survival analysis, and dif-
ferences in survival were estimated using the log-rank test. A mul-
tivariate survival analysis was performed for all parameters that
were signiﬁcant in the univariate analyses using the Cox regression
model. Differences were considered statistically signiﬁcant when P
was less than 0.05.3. Results
3.1. MiRNA-101 directly targets SOX9 in HCC tissues
Our previous study performed by qRT-PCR, immunohistochem-
istry, and Western blot has demonstrated that SOX9 is up-
regulated in human HCC tissues at both mRNA and protein levels
[15]. In the present study, using miRNA target predicting program
(TargetScan human 6.2), there was only one miRNA—miR-101
which is hypothesized as a candidate miRNA that targets SOX9
(Fig. 1A), but other known direct regulators of SOX9, such as
miR-145 [16,17], were not predicted. Different from other ap-
proaches, TargetScan requires perfect complementarity to the seed
region of a miRNA and then extends these regions to unravel com-
plementarity outside the region [18]. Thus, it features an efﬁcient
reduction in the false-positive rate but, because of its required
strict complementarity in the seed region, loosely conserved tar-
gets and those containing wobble pairings are more likely to be
missed [19].
Then, we performed qRT-PCR, transient transfection of the HCC
cell line HepG2 with miR-101 vector plasmid, and luciferase repor-
ter assay to test our hypothesis. In order to validate the speciﬁcity
of this test system, hsa-miR-145 vector was used as the positive
control because it has been demonstrated to be a direct regulator
of SOX9 by previous studies [16,17]. According to the results of
qRT-PCR analysis, miR-101 and miR-145 (positive control) expres-
sion in HCC tissues were both signiﬁcantly lower than those in
adjacent non-neoplastic liver tissues [for miR-101: HCC tissues
vs. normal liver tissues: 0.87 ± 0.45 vs. 1.74 ± 0.78, P < 0.001,
Fig. 1B; for miR-145: HCC tissues vs. normal liver tissues:
0.82 ± 0.39 vs. 1.79 ± 0.62, P < 0.001, Fig. 1C].
To verify our predicted target of hsa-miR-101, we transfected
HepG2 cells with hsa-miR-101 vector, hsa-miR-145 vector
(positive control), negative vector (NC), and blank control culture
medium (mock). Western blot analysis showed that, at 24 h
post-transfection, the overexpressions of hsa-miR-101 and has-
miR-145 both resulted in a signiﬁcant decrease of endogenous
SOX9 protein levels, compared with cells transformed with NC or
mock (HepG2 cells transfected with hsa-miR-101 vector vs. those
Fig. 1. MiRNA-101 (miR-101) directly targets SOX9 in hepatocellular carcinoma (HCC) tissues. (A) MiR-101 is predicted to target SOX9. (B) and (C) MiR-101 and miR-145 are
both downregulated in human HCC tissues detected by qRT-PCR analysis. (D) and (E) The relative expression levels of SOX9 protein in HepG2 cells detected by Western blot
analysis at 24 h post-transfection of miR-101 and miR-145 vectors, respectively. GAPDH was used as an internal loading control. Negative control vector (NC). (F) Luciferase
report assay was performed to conﬁrm the miR-101 binding target. The luciferase activity was detected after co-transfection of FLuci vector (30-UTR-SOX9wt FLuci vector or
30-UTR-SOX9mut FLuci vector), miR-101 mimic or negative mimic into HepG2 cells. ⁄P < 0.001, comparison with HepG2 cells co-transfected with 30-UTR-SOX9wt FLuci vector
and miR-101 mimic.
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cells transfected with hsa-miR-145 vector vs. those with negative
vector: 0.49 ± 0.07 vs. 1.63 ± 0.15, P = 0.001; Fig. 1D and E). As well
as the over-expression of miR-101, SOX9 knockdown by SOX9 siR-
NA markedly reduced the endogenous SOX9 protein levels of
HepG2 cells (Fig. 2).
Furthermore, to verify whether SOX9 was a direct target of miR-
101, the luciferase reporter assay was performed by co-transfec-
tion of miR-101 and a luciferase reporter plasmid containing the30 UTR of human SOX9. Luciferase activity was detected at 48 h
after the co-transfection of FLuci vector (30-UTR-SOX9wt FLuci vec-
tor or 30-UTR- SOX9mut FLuci vector), miR-101 mimic or NC mi-
mic, and RLuci vector in HepG2 cells. As shown in Fig. 1E, the
luciferase activity was decreased to 0.53 in HepG2 cells co-trans-
fected with 30-UTR-SOX9wt FLuci vector and miR-101 mimic com-
pared with 30-UTR-SOX9mut FLuci vector and NC mimic (Fig. 1F).
Taken together, these observations suggested that miR-101 di-
rectly target SOX9.
Fig. 2. Down-regulation of SOX9 by siRNA interference. Western blot analysis was performed to detect the expression levels of SOX9 protein in SOX9 siRNA-transfected
(HepG2-S), control siRNA-transfected (HepG2-C) and non-transfected (HepG2) cells. GAPDH was used as an internal loading control.
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targeting SOX9
The down-regulation of miR-101 in HCC tissues comparing with
adjacent non-neoplastic liver tissues prompted us to determine
whether miR-101 functions as a tumor suppressor. Compared with
normal human liver cell line HL-7702, the expression level of miR-
101 in HCC cell line HepG2 was markedly decreased (HepG2 vs.
HL-7702: 2.17 ± 0.31 vs. 3.20 ± 0.36, P = 0.001; Fig. 3A). In line with
the results of miR-145 (positive control, P = 0.02), the enforced
expression of miR-101 signiﬁcantly inhibited cell proliferation of
HepG2 cells (P = 0.02; Fig. 3B). Meanwhile, HepG2 cells expressing
SOX9 siRNA showed signiﬁcant decrease in cell proliferation, com-
pared to HepG2 cells transfected with control siRNA (P = 0.01,
Fig. 3C). To further verify whether miR-101 inhibited cell prolifer-
ation of HCC cell line through SOX9, we made use of HCC cell line
HepG2 cells in which SOX9 was knocked down by SOX9 siRNA
transfection. As shown in Fig. 3D and E, the enforced expression
of miR-101 signiﬁcantly inhibited cell proliferation of HepG2 cells
transfected with control siRNA (P = 0.02, Fig. 3D) but failed to do so
in HepG2 cells transfected with SOX9 siRNA (P > 0.05, Fig. 3E).
Therefore, miR-101 may inhibited cell proliferation of HepG2 cells
by targeting SOX9.
3.3. MiR-101 inhibits human HCC cells migration and invasion in vitro
by targeting SOX9
To determine the function of miR-101 on tumorigenicity of HCC
cells, we performed the in vitro invasion and migration assay byestablishing miR-101-expressing HCC transfectants with hsa-
miR-101 vector. In line with the results of miR-145 (positive
control), enforced expression of miR-101 inhibited the migratory
ability of HCC cells as indicated by the decrease in migrated cells
in the Transwell cell migration assay (P = 0.002, Fig. 4A). A similar
result was observed in the cell invasion assay (P = 0.004, Fig. 4A).
As well as the ﬁndings of miR-101 overexpression, SOX9 siRNA
transfection also signiﬁcantly inhibited the cell migration and
invasion of HepG2 cells compared with the control cells at 48 h
after transfection (both P = 0.002, Fig. 4B). To further verify
whether miR-101 inhibited the cell migration and invasion of
HCC cell line through SOX9, we made use of HCC cell line HepG2
cells in which SOX9 was knocked down by SOX9 siRNA transfec-
tion. As shown in Fig. 4C and D, the enforced expression of miR-
101 signiﬁcantly inhibited the cell migration and invasion of
HepG2 cells transfected with control siRNA (both P = 0.004,
Fig. 4C) but failed to do so in HepG2 cells transfected with SOX9
siRNA (both P > 0.05, Fig. 4D). Therefore, miR-101 may suppress
HCC metastasis via negatively regulating the migratory and inva-
sive abilities of HCC cells by targeting SOX9.
3.4. Down-regulation of miR-101 associates the advanced tumor
progression of human HCC
To evaluate whether miR-101 expression was associated with
clinicopathological features of patients with HCC, we analyzed
the association of miR-101 expression with T stage, tumor grade,
presence of cirrhosis, underlying liver disease including alcohol
abuse, viral hepatitis B and C, sex, and age (Table 1). Based on
Fig. 3. MiRNA-101 (miR-101) inhibits cell proliferation of hepatocellular carcinoma (HCC) cells in vitro by targeting SOX9. (A) miR-101 expression in normal human liver cell
line HL-7702, HCC cell line HepG2, and HepG2 cells transfected with miR-101 (HepG2_miR-101) or negative control (HepG2_NC); (B) Growth curves of HepG2 cells following
transfection with miR-101 (HepG2_miR-101), miR-145 (HepG2_miR-145, positive control) or negative control (HepG2_NC); (C) Growth curves of SOX9 siRNA-transfected
(HepG2-S), control siRNA-transfected (HepG2-C) and non-transfected (HepG2) cells; (D) Growth curves of HepG2 cells transfected with control siRNA (HepG2-C), and HepG2
cells transfected with control siRNA and miR-101 (HepG2-C-miR-101); (E) Growth curves of HepG2 cells transfected with SOX9 siRNA (HepG2-S), and HepG2 cells transfected
with SOX9 siRNA and miR-101 (HepG2-S-miR-101).
Y. Zhang et al. / FEBS Letters 586 (2012) 4362–4370 4367the median value (0.80) of miR-101 expression, all patients were
divided into two groups including group with low expression of
miR-101 (n = 75) and group with high expression of miR-101
(n = 55). As the results, the down-regulation of miR-101 was more
frequently found in the higher tumor stage (T3–4) and tumor grade
(G3) than in the lower tumor stage (T1–2, P = 0.02) and tumor
grade (G1–2, P = 0.008), respectively.
3.5. Down-regulation of miR-101 associates poor prognosis of patients
with HCC
Five-year disease-free survival was observed in 30 (23.08%) pa-
tients, whereas in 100 (76.92%) patients, disease recurred, and 88
(67.69%) even died during a 5-year follow-up period. We observed
a trend that 5-year disease-free survival in the group with low
miR-101 expression was signiﬁcantly poorer than that in the group
with high miR-101 expression (P = 0.01, log-rank test; Fig. 5A).
Additionally, the Kaplan–Meier plot of 5-year overall survival
curves stratiﬁed by miR-101 expression was shown in Fig. 5B. A
signiﬁcant relationship was found between miR-101 expression
and 5-year overall survival (P = 0.006, log-rank test, Fig. 5B).
Furthermore, in a multivariate Cox model, including tumor size,
tumor stage, tumor grading, presence of cirrhosis, gender, age,and miR-101 expression, we found that miR-101 expression was
an independent poor prognostic factor for both 5-year disease-free
survival (hazards ratio [HR] = 2.56, 95% conﬁdence interval
[CI] = 1.32–5.69, P = 0.02, Table 2) and 5-year overall survival
(HR = 3.27, CI = 1.18–6.92, P = 0.01, Table 2) in HCC.
4. Discussion
HCC is a complex and heterogeneous disease with multiple
underlying pathogenic mechanisms caused by various risk factors.
It is of great signiﬁcance to identify novel and effective molecular
markers for HCC diagnosis and treatment assessment. Here, the
main ﬁndings of the present study are as following ﬁve points.
Firstly, the miRNA target prediction program TargetScan was used
to predict an miRNA—miR-101 as a candidate regulator for SOX9
expression. Using human HCC cell line HepG2 transfected with
miR-101 overexpression vector, we further validated that SOX9
was down-regulated at protein level by the proposed target miR-
NA, miR-101, which was also conﬁrmed by the luciferase reporter
assay, suggesting that miRNA-101 directly targets SOX9 in HCC tis-
sues. Secondly, the expression level of miR-101 was decreased
both in clinical HCC tissues and HCC cell line in vitro. Thirdly, the
down-regulation of miR-101 in clinical HCC tissues was associated
Fig. 4. MiRNA-101 (miR-101) inhibits human hepatocellular carcinoma (HCC) cell migration and invasion by targeting SOX9. (A) Transwell migration assay and Matrigel
invasion assay of HepG2 cells transfected with miR-101 vector (HepG2_miR-101), miR-145 (HepG2_miR-145, positive control) or negative control (HepG2_NC) vector
showed that the over-expression of miR-101 and miR-145 both caused a two- to threefold decrease in cell migration and invasion. ‘’ refers to P < 0.05 when compared with
HepG2_NC group. (B) Transwell migration assay and Matrigel invasion assay of SOX9 siRNA-transfected (HepG2-S), control siRNA-transfected (HepG2-C) and non-transfected
(HepG2) cells. ‘’ refers to P < 0.05 when compared with HepG2_C group. (C) Transwell migration assay and Matrigel invasion assay of HepG2 cells transfected with control
siRNA (HepG2-C), and HepG2 cells transfected with control siRNA and miR-101 (HepG2-C-miR-101). (D) Transwell migration assay and Matrigel invasion assay of HepG2
cells transfected with SOX9 siRNA (HepG2-S), and HepG2 cells transfected with SOX9 siRNA and miR-101 (HepG2-S-miR-101). Enforced expression of miR-101 signiﬁcantly
inhibited the cell migration and invasion of HepG2 cells transfected with control siRNA (HepG2-C-miR-101 vs. HepG2-C) but failed to do so in HepG2 cells transfected with
SOX9 siRNA (HepG2-S-miR-101 vs. HepG2-S). ‘’ refers to P < 0.05 when compared with HepG2-C.
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patients. Fourthly, enforced expression of miR-101 and knockdown
of SOX9 by siRNA both inhibited the cell proliferation and tumor-
igenicity of HCC cell line in vitro. Finally, miR-101 overexpression
did not inhibit the cell proliferation and tumorigenicity of HCC
cells in vitro when SOX9 was knocked down. These results suggest
that SOX9 direct regulator miR-101 is the potential tumor suppres-
sor miRNA for HCC.
MiRNAs have been demonstrated to regulate multiple cellular
pathways by modulating the expression of various target genes
[20]. MiRNA proﬁle can reveal prospective features in cancer. Espe-
cially in HCC, dozens of miRNAs have been reported to be involved
in tumorigenesis and tumor progression. However, the functions
and real targets of miRNAs were largely unknown. In the present
study, we focus on miR-101, a tumor suppressive miRNA [21].
The down-regulation of miR-101 has been found in a variety of hu-
manmalignancies including breast cancer, prostate cancer, bladder
cancer, epithelial ovarian carcinoma, liver cancer, colon cancer,
lung cancer and gastric cancer [22–26]. This miRNA functions its
tumor-suppressive effects by inhibiting cell migration, invasion,
proliferation, and promoting apoptosis by regulating different
oncogenes in different cancer type. Semaan et al. [27] revealed that
the overexpression of miR-101 in epithelial ovarian carcinoma
cells may increase apoptosis, decreased cellular proliferation,
invasiveness, and reduced growth of tumor xenografts by inhibit-
ing the interaction of EzH2 with p21waf1/cip1 promoter; Wang
et al. [28] indicated that the ectopic expression of miR-101
signiﬁcantly inhibits cellular proliferation, migration and invasion
of gastric cancer cells by targeting EZH2, COX-2, Mcl-1 and FOS.
Especially in HCC, research done by Su et al. [29] in 2009
demonstrated that ectopic expression of miR-101 dramaticallysuppressed the ability of hepatoma cells to form colonies in vitro
and to develop tumors in nude mice. They also found that miR-
101 could signiﬁcantly reduced the endogenous protein level of
Mcl-1, whereas the miR-101 inhibitor obviously up-regulated
Mcl-1 expression and inhibited cell apoptosis. In the same year,
both luciferase reporter assay and western blot analysis done by
Li et al. [30] demonstrated that enforced expression of miRNA-
101 in HCC represses the expression of an oncogene FOS, a key
component of the activator protein-1 (AP-1) transcription factor.
The current study demonstrated that SOX9 is another direct target
of miR-101 in HCC cells. As intra-hepatic metastasis is the major
characteristic of HCC, it is necessary to identify molecular events
contributing to HCC metastasis to ﬁnd an effective therapeutic
treatment for metastatic HCC. Here, we demonstrated that miR-
101, as well as miR-145 which has been demonstrated to be a
direct regulator of SOX9 by previous studies [16,17], were func-
tionally involved in suppressing HCC cell migration and invasion,
which was supported by both clinical data and cell culture studies.
In clinical samples, miR-101 was dramatically down-regulated in
HCC with high tumor stage and grade compared with HCC with
low tumor stage and grade, and low miR-101 expression in tumors
was associated with poor survival of HCC patients. Regarding to
miR-145, our data also showed its downregulation in HCC com-
pared with adjacent non-neoplastic liver tissues, which was con-
sistent with the ﬁndings of Karakatsanis et al. [31]. In cell culture
experiments, over-expression of miR-101 and miR-145 both re-
sulted in decreased HCC cell proliferation and cell motility. More
importantly, we conﬁrmed that miR-101 functions as a tumor sup-
pressor for HCC by targeting SOX9.
In conclusion, our data offer the ﬁrst convinced evidence that
miR-101 may suppress tumor progression of HCC through
Fig. 5. Kaplan–Meier survival curves for miR-101 expression in hepatocellular carcinoma (HCC) patients. The HCC patients with lowmiR-101 expression showed signiﬁcantly
shorter disease-free survival (P = 0.01, A) and overall survival (P = 0.006, B) rates than those with high miR-101 expression.
Table 2
Multivariate survival analysis of ﬁve-year overall and disease-free survival in 130
patients with hepatocellular carcinoma.
Features Five-year overall
survival
Five-year disease-free
survival
HR 95% CI P HR 95% CI P
Age 1.13 0.32–3.52 0.19 1.54 0.32–3.74 0.13
Gender 1.19 0.35–3.86 0.14 1.56 0.36–3.83 0.13
Tumor size 1.93 0.69–4.06 0.06 1.95 0.62–4.27 0.06
Tumor stage 2.88 1.37–5.20 0.01 2.69 1.39–6.01 0.01
Tumor grade 1. 56 0.61–4.09 0.08 1.55 0.61–4.47 0.09
Presence of cirrhosis 1.92 0.74–4.10 0.06 1.92 0.79–4.22 0.06
MiR-101 expression 3.27 1.18–6.92 0.01 2.56 1.32–5.69 0.02
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